TORONTO, Nov. 11, 2011 /CNW/ - Biosign Technologies Inc. (TSXV: BIO) announces today that their European distribution partner MedVec, in
cooperation with partner company Ulti Med Products (Deutschland) GmbH,
will showcase Biosign solutions, including the UFIT® TEN-10 Blood
Pressure monitor and cardiovascular health software at MEDICA in
Dusseldorf Germany, November 16-19 in Hall 3, Booth 41.
"Cardiovascular disease (CVD) is the leading cause of death in Germany
with more than 400,000 fatalities a year linked directly to CVD. The
German social health system spends over €40 billion (about $60 billion
U.S.) each year on CVD," said MedVec Founder & CEO Mr. Knut Butzinger.
"Biosign offers patients, caregivers and payers accurate cardiovascular
health data that will improve quality of care and reduce costs
associated with CVD. The UFIT health monitor could provide warning
alerts that would flag 'at risk' patients for early interventions,
reducing costs associated with emergency care. We are very excited
about offering Biosign's technology to the state agencies and
organizations we work with."
MedVec International is headquartered in Neckargemünd, Germany (near
Heidelberg) and specializes in marketing, sales and distribution of
innovative diagnostic technologies covering women's health, family
health and diabetes to Germany, France, Austria and several other
European countries. The German Pharmacists Association (BDA) recently
awarded the MedVec "Yes or No" early detection pregnancy test "Medical
Product of the Year 2011."
"Cardiovascular disease screening and monitoring could turn the tide on
CVD medical costs in Germany," said Dr. Scott Jenkins, Biosign CEO.
"Partnerships with best in class providers like MedVec allow us to work
closely with German healthcare organizations and provide customized
solutions that meet specific localized needs."
MEDICA is considered the premier Global Medical Industry trade show and
exhibition which regularly features 4,400 exhibitors. MEDICA is known
to have up to 138,000 participants from over 100 countries looking at
the current and potential future trends for patient care.
About Biosign Technologies Inc.
Biosign Technologies Inc. (TSXV: BIO) provides biomedical systems. Key
applications include intelligent systems for noninvasive monitoring of
common health risks associated with blood pressure, life style and
medication. The core technology combines measurement, analysis, and
rapid knowledge formation to support health monitoring across global
markets. The UFIT® medical device technology powers quality data
collection and analytics for clinical diagnostics, self-care, wellness,
disease state evaluation & management, and remote patient monitoring.
For more information, please visit www.biosign.com.
This release contains forward-looking statements. Forward-looking
statements, without limitation, may contain the words believes,
expects, anticipates, estimates, intends, plans, or similar
expressions. Forward-looking statements are not guarantees of future
performance. They involve risks, uncertainties and assumptions and
Biosign's actual results could differ materially from those
anticipated. Forward looking statements are based on the opinions and
estimates of management at the date the statements are made, and are
subject to a variety of risks and uncertainties and other factors that
could cause actual events or results to differ materially from those
projected in the forward-looking statements. In the context of any
forward-looking information please refer to risk factors detailed in,
as well as other information contained in, Biosign's filings with
Canadian securities regulators www.sedar.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.
SOURCE Biosign Technologies Inc.
For further information:
Dr. Scott Jenkins, CEO
Biosign Technologies Inc.
Phone: (416) 218-9800 ext. 234